Sarepta Therapeutics Ownership
| SRPT Stock | USD 74.10 0.65 0.88% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 100 M | Current Value 108 M | Avarage Shares Outstanding 54.6 M | Quarterly Volatility 27.7 M |
Sarepta |
Sarepta Stock Ownership Analysis
About 92.0% of the company shares are owned by institutional investors. The book value of Sarepta Therapeutics was at this time reported as 15.77. The company had not issued any dividends in recent years. Sarepta Therapeutics had 1:6 split on the 12th of July 2012. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Sarepta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 840 people. To find out more about Sarepta Therapeutics contact Douglas Esq at 617 274 4000 or learn more at https://www.sarepta.com.Besides selling stocks to institutional investors, Sarepta Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Sarepta Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Sarepta Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Sarepta Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Sarepta Therapeutics Insider Trades History
About 4.0% of Sarepta Therapeutics are currently held by insiders. Unlike Sarepta Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Sarepta Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Sarepta Therapeutics' insider trades
Sarepta Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sarepta Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sarepta Therapeutics backward and forwards among themselves. Sarepta Therapeutics' institutional investor refers to the entity that pools money to purchase Sarepta Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 1.7 M | Deutsche Bank Ag | 2024-12-31 | 1.7 M | Ubs Group Ag | 2024-12-31 | 1.5 M | Groupama Asset Management | 2024-12-31 | 1.3 M | Casdin Capital, Llc | 2024-12-31 | 1.1 M | Pictet Asset Manangement Sa | 2024-12-31 | 1 M | Norges Bank | 2024-12-31 | 1 M | Camber Capital Management Llc | 2024-12-31 | 1000 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 991.7 K | Blackrock Inc | 2024-12-31 | 11.2 M | Vanguard Group Inc | 2024-12-31 | 9.1 M |
Sarepta Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sarepta Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sarepta Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sarepta Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sarepta Therapeutics Outstanding Bonds
Sarepta Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sarepta Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sarepta bonds can be classified according to their maturity, which is the date when Sarepta Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Sarepta Therapeutics Corporate Filings
F4 | 13th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
ASR | 3rd of March 2025 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
10K | 28th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 26th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.